Nature Communications (Apr 2020)

Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer

  • Dingxiao Zhang,
  • Qiang Hu,
  • Xiaozhuo Liu,
  • Yibing Ji,
  • Hsueh-Ping Chao,
  • Yan Liu,
  • Amanda Tracz,
  • Jason Kirk,
  • Silvia Buonamici,
  • Ping Zhu,
  • Jianmin Wang,
  • Song Liu,
  • Dean G. Tang

DOI
https://doi.org/10.1038/s41467-020-15815-7
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 19

Abstract

Read online

Dysregulation of mRNA alternative splicing is prevalent in cancers. Here, the authors characterized the landscape of aberrant alternative splicing during the development of prostate cancer, progression and therapeutic resistance and show that splicing modulator, E7107, reduces growth in castration-resistant prostate cancer.